About Event

Welcome to the 3rd Cytokine-Based Drug Development Summit

The renewed interest in the anti-tumour properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs. Soluble factors within the tumor microenvironment (TME) orchestrating a variety of wide-ranging biologic effects and interventions in this field can help stimulate immunotherapeutic responsiveness.

The 3rd Cytokine-Based Drug Development Summit will give drug developers insight into the latest clinical results and stimulate discussions around how to take immuno-oncology combinations forward

This is your opportunity to join your peers from industry and academia to discuss key topics including:

fav icon - cytokine (2)

Delve into cytokine research beyond oncology, understand application & translation in inflammatory diseases

fav icon - cytokine (2)

Uncover the latest data coming out of the clinic of cytokines in combination with checkpoint inhibitors and monoclonal antibodies

fav icon - cytokine (2)

Overcome toxicity challenges by ensuring tumor targeting is selective and therefore enhances the anti-tumor response

fav icon - cytokine (2)

Take a deep dive into preclinical cancer models covering both invitro and in-vivo studies and how these are unveiling the most favoured pharmaceuticals properties of therapeutic cytokines

fav icon - cytokine (2)

Network in person with all attendees, ask your burning questions, build connections and fully immerse yourself in the world of cytokines